Mint Explainer: How can Indian drugmakers blunt the impact of Trump’s generic tariffs?

Mint has reported a new India-focused technology development: “Mint Explainer: How can Indian drugmakers blunt the impact of Trump’s generic tariffs?.” The publisher's feed describes the story as follows: From local outsourcing and tech transfers to passing costs on to American consumers, pharmaceutical firms are weighing tactical options to protect their margins. Intellectual Janata Party includes this item for public-affairs discovery and context only; readers should use the original publish
Intellectual Janata displays only original summaries of externally sourced news and links readers to the original publisher.

